Regeneron Pharmaceuticals, Inc. (REGN) Presents at Barclays 28th Annual Global Healthcare Conference Transcript

Regeneron management told investors at the Barclays Healthcare Conference that the stock appears materially undervalued because current market valuation largely reflects only DUPIXENT, the EYLEA franchise and cash on hand. SVP Ryan Crowe argued those durable cash flows underpin the company and that successful pipeline readouts would meaningfully increase intrinsic value. The presentation frames a bullish investor thesis that pipeline upside is not priced in and supports a buy view.

Analysis

The market is under-discounting Regeneron’s optionality: durable cash generation from core franchises funds a portfolio of mid-to-late stage assets that can re-rate the equity without meaningful dilution. If even two mid-stage programs convert to approval over 24–36 months, the upside could be nonlinear because each approval leverages existing commercial infrastructure and manufacturing scale, compressing time-to-profitability versus a greenfield launch.

Competitive dynamics favor vertically integrated biologics incumbents and their CDMO partners. Success at Regeneron forces rivals to either accelerate high-cost follow-on programs or concede share, benefiting contract manufacturers and single‑use bioreactor suppliers in the near term while pressuring smaller, undercapitalized immunology specialists.

Key catalysts that will drive re-rating are next 6–18 month guidance updates, pivotal readouts, and labeling/regulatory milestones; the principal tail risks are binary clinical failures, accelerated biosimilar entry in ophthalmology, or payer-driven unit‑price compression. These risks are asymmetric — failures are immediate and binary, while successes compound through cross-selling and long-duration payor contracts over multiple years.

The trade framework should therefore express concentrated exposure to company-specific upside while limiting downside from binary events and sector moves. Use time horizons of 6–36 months for tactical positions (earnings/guidance) and 12–48 months for option structures that capture pipeline optionality.

Key Decisions for Investors

• Buy REGN (size 2–4% of liquid equity book) and hold 12–24 months to capture multiple pipeline catalysts; target asymmetric upside of 30–60% if 1–2 late-stage programs succeed, with stop-loss at -12% to protect from binary clinical shocks.
• Purchase REGN Jan-2027 call spread (buy 1x 25% OTM call / sell 1x 60% OTM call) to capture multi-year pipeline optionality while capping premium — expected payoff 2–4x on a 30–50% stock move, max loss = premium paid.
• Pair trade: long REGN / short XBI (equal dollar) for a 6–12 month tactical play to isolate company-specific catalysts from sector volatility; reduce pair size if sector risk rises ahead of broad macro events.
• Tactical hedge ahead of binary readouts: buy 3–6 month REGN 10% OTM puts sized at 25–33% of the long position to limit downside from surprise negative news while retaining upside exposure.